Karen Addis is vice president, U.S. Health Sciences Practice at Environics Communications in Washington, D.C.
Anik Alam is the vice president of the AAPS Duquesne University student chapter, a graduate student in pharmaceutical sciences, and former executive in SQUARE Pharmaceuticals Ltd.
Geoffrey Banks, Ph.D., is the CEO and founder of ClinPharm Consulting, a leading consulting firm focused on clinical pharmacology and pharmacokinetic services for biopharmaceutical companies. Banks received his doctorate in protein biochemistry with a research focus on recombinant human protein expression and characterization. Following a post-doctoral appointment at the National Institutes of Health in biologics, Banks transitioned to pharmaceutical drug development with a focus on clinical pharmacology and has an established track record of clinical, regulatory, and entrepreneurial success within the pharmaceutical industry.
Robert G. Bell, Ph.D., is president and owner of Drug and Biotechnology Development LLC, a consultancy to the pharmaceutical industry and academia for biological, drug, and device development. His research interests include pharmaceutical and biomedical analysis, chemistry, manufacturing, and control, quality, vaccines, biosimilar proteins, women’s health products, oncology therapeutics, and green chemistry initiatives.
Karl Box is head of research and development, Sirius Analytical Instruments, where his responsibilities include leading instrumentation and assay development for physicochemical property evaluation.
Thomas Cook, Ph.D., R.Ph. is an associate professor and director of program assessment at Touro College of Pharmacy in New York City. Tom has been in academia since 1999. He earned his doctorate from the University of Michigan (1995), and he was chair of the Teachers of Pharmaceutics Section of the American Association of Colleges of Pharmacy (2011–2012).
Anne De Groot
Anne De Groot, M.D., is professor and director at the University of Rhode Island Institute for Immunology and Informatics. She is internationally known for her research on the human immune system’s response to vaccines and therapeutics. She is founder, CEO, and chief scientific officer of EpiVax (est. 1998), which seeks to accelerate the development of vaccines that are inexpensive, easy to manufacture, and easily shipped around the globe. She is also the founder and scientific director of the Institute for Immunology and Informatics—the first center of excellence focused on immunoinformatics in the world—at the University of Rhode Island.
Elizabeth de Lange
Elizabeth (Liesbeth) de Lange, Ph.D., is head of the Target Site Equilibration Group at the Leiden Academic Centre for Drug Research, Division of Pharmacology, The Netherlands. She aims to contribute to the scientific basis for prediction of human central nervous system drug effects by translational model development on the basis of preclinical data. Her research focusses on the development of generally applicable (physiologically based) pharmacokinetic/pharmacodynamic models using advanced in vivo animal models and pharmacometrics. It involves identification and characterization of condition-dependent contribution of key factors in this relationship using the “mastermind approach.”
Divyakant Desai, Ph.D., is a Research Fellow in the Bristol-Myers Squibb Company. He has been working in the area of oral dosage form for the last 24 years and was the lead formulator for nine commercial products. His research interests involve designing quality formulations and addressing stability and manufacturing process related issues.
Prapti Desai worked as an intern with AAPS in the summer of 2012. She is a recent graduate with a master’s degree in molecular medicine from the University of Maryland, Baltimore and is looking for a full-time research position in the biotech/pharma industry.
Tony DeStefano, Ph.D., is the 2013 AAPS president and has over 30 years of experience in the pharmaceutical sciences, including at the United States Pharmacopeial Convention and Procter & Gamble.
Megan Driscoll is the founder of PharmaLogics Recruiting and also serves as the president of the company. She has been recruiting in the biotechnology/pharmaceutical industry for over 15 years. Megan is the author of I would consider any reasonable offer: A Guide to Successfully Interviewing in the Biotech or Pharmaceutical Industry and has been a career development speaker for the American Association of Pharmaceutical Scientists, the American Library Association, the International Society for Pharmaceutical Engineering, and the Biotechnology Industry Organization for the last five years.
Abimbola Farinde, Pharm.D., M.S., FASCP, is a clinical pharmacist specialist with specializations in psychopharmacology and geriatrics. Farinde is an adjunct pharmacology instructor and an associate editor of several healthcare and scientific journals.
Sam Gilchrist, Ph.D., is a new graduate currently working as a medical and scientific liaison in the pharmaceutical industry. Sam has been heavily involved with AAPS as president of the University of British Columbia student chapter for two years, a member of the Finance Committee for two years, a member-at-large for one year, and remains active as a member of the Student/Postdoctoral Outreach & Development committee. He received his bachelor’s degree from St. Francis Xavier University (2003), master’s degree from the University of Saskatchewan (2007), and doctorate from the University of British Columbia (2012).
Ted Grasela is the president and CEO of Cognigen Corporation, adjunct professor of pharmaceutics at the University at Buffalo, and the 2013 winner of the Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology and Therapeutics.
Teresa R. Henry, Ph.D., currently serves as the associate director of quality control at Optimer Pharmaceuticals, Inc. and is a steering committee member of the AAPS Non-Clinical Dose Form Analysis focus group. With more than 15 years in the industry, Teresa has worked in several regulated industries ranging from food to pharmaceuticals and in many stages of drug development ranging from IND-enabling formulation analysis and bioanalysis through commercial stability and release.
Abhay Joshi is a Ph.D. student in pharmaceutics at Long Island University. His research interests are in microdialysis and pharmacokinetic and pharmacodynamic modeling.
Prasanna Kolluru is a Ph.D. candidate at Mercer University under Martin D’Souza, Ph.D. Kolluru works on development of theragnostic nanoparticles for tumor targeted drug delivery. In her free time, Kolluru enjoys penning down articles for newspaper columns.
Elizabeth Kwong, Ph.D., retired from Merck & Co., Inc., after 23 years of service. She then established her own company, Kwong Eureka Solutions, as a consultant for small start-up companies and specialty drug products. She is also an adjunct professor in the Department of Pharmaceutics at the University of Montreal and Department of Chemistry at Concordia University and received her bachelor’s in pharmacy (1980) and doctorate in pharmaceutical chemistry (1984) from the University of British Columbia, Canada.
Karin Liltorp, Ph.D., is currently working as principal scientist at Particle Analytical Aps., an analytical laboratory performing physical chemical characterization of pharmaceutical drugs. Previously, she worked for six years at Lundbeck as a preformulation scientist with her primary focus on poorly soluble drugs, including computer simulations and formulation development. Karin received her doctorate in physical chemistry from Roskilde University.
Pramod B. Mahajan
Pramod B. Mahajan, Ph.D., is an associate professor of pharmaceutical sciences at Drake University, College of Pharmacy & Health Sciences. He is also chair of the AAPS Pharmacogenomics focus group.
Hanns-Christian Mahler, P.D., Ph.D., is head of pharmaceutical development and supplies, PTD Biologics EU, F.Hoffmann-LaRoche Ltd (Basel, Switzerland). He is currently responsible for early stage and late stage pharmaceutical development, including formulation and process development, clinical supplies (preclinical and clinical drug product manufacturing) and primary packaging development of biotech and NCE parenteral research and development projects, and parenteral marketed product and production support. He additionally holds university teaching positions at the University of Frankfurt/Main, Germany, and University of Basel, Switzerland. Hanns-Christian is immediate past chair of the AAPS Protein Aggregation & Biological Consequences focus group.
Marilyn Martinez, Ph.D., is a senior biomedical research scientist with the Food and Drug Administration where she heads the pharmacokinetics team within the Office of New Animal Drug Evaluation of the Center for Veterinary Medicine. Serving as a resource for bridging between human and veterinary medicine, she is also an AAPS Fellow and an associate editor of The AAPS Journal.
David Y. Mitchell
Dave Mitchell, Ph.D., is the current president of AAPS and the president of Mitchell Pharmaceutical Consulting, which has a primary focus on clinical pharmacology. He received his bachelor’s in biological sciences from the University of Northern Colorado and his doctorate in pharmaceutical sciences from the University of Colorado. Mitchell has more than 18 years of pharmaceutical and biotechnology experience in clinical pharmacology, project leadership, and strategic drug development.
David Monteith, Ph.D., is currently associate vice president and head of emerging markets pharmaceutical development at Merck & Co. David earned his pharmacy degree and doctorate from the University of Strathclyde and subsequently obtained a master’s degree in administration from the University of Warwick. He has primarily worked on the development and commercialization of drug products utilizing novel drug delivery technologies during his 20+ years in the industry.
Hadik Mody is currently a second year graduate student in the Department of Pharmaceutical and Biomedical Sciences, University of Georgia, College of Pharmacy. He is the vice chair of the AAPS Biotechnology section student committee.
Johanna Mora, Ph.D., is a senior research investigator responsible for regulated bioanalysis of
biotherapeutics in support of GLP and clinical studies in the Department of Immunochemistry and Biomarker Development at Bristol-Myers Squibb (BMS). She leads a team of scientists in the bioanalysis of macromolecular therapeutics for pharmacokinetics, immunogenicity, and discovery support and is also responsible for development and execution of novel technologies and scientific strategy for bioanalysis of protein therapeutics. She is an active member of AAPS and serves in the Emerging Technologies Action Program Committee within the AAPS Ligand Binding Assay Bioanalytical focus group and has served the Applied Pharmaceutical Analysis Regulated Committee since 2011.
Marilyn Morris, Ph.D., is professor of pharmaceutical sciences, School of Pharmacy and Pharmaceutical Sciences, and associate dean in the graduate school, University at Buffalo, State University of New York. Her research focuses on the influence of drug transporters on drug pharmacokinetics and pharmacodynamics. Marilyn is an associate editor for The AAPS Journal , an AAPS Fellow, and the 2013 AAPS president-elect.
Brian Moyer is currently contracted to the Biomedical Advanced Research and Development Authority, Health and Human Services, Washington, D.C., as senior science advisor, Project BioShield, Chemical, Radiologic and Nuclear Threats, through Tunnell Government Services, Bethesda, Md. He owns and operates his consulting firm, BRMoyer & Associates, LLC, out of Bedford, N.H., specializing in imaging systems and approaches for drug development, radiation and chemical injury medical countermeasures, and pharmacokinetics and toxicokinetics of drugs and biologics. He is the chair for the AAPS Pharmaco-Imaging focus group and on the National Biotechnology Conference Planning Committee representing the Pharmacokinetics, Pharmacodynamics, and Drug Metabolism section.
Nisha Nanaware-Kharade, M.S. (Pharm.), is the current chairperson of the AAPS University of Arkansas for Medical Sciences student chapter. She is also the AAPS National Biotechnology Conference liaison for the AAPS Biotechnology section student committee and secretary of the AAPS Pharmacogenomics focus group.
Edward Narke is regulatory managing director and cofounder, Design Space InPharmatics.
James Polli, Ph.D., is a professor at the University of Maryland School of Pharmacy and a member-at-large on the AAPS Executive Council.
Andrew Porterfield has been a marketing communications consultant for biotechnology and pharmaceutical firms, research institutes, and universities, and a science journalist and blogger for sites around the world for more than 20 years. He lives in California, and has a master’s degree in biotechnology management from the University of Maryland, and a bachelor’s degree from the University of Pennsylvania.
Margaret Speed Ricci is director of drug product development at Amgen, Inc., in Thousand Oaks, Calif. She has a Bachelor of Science in chemical engineering from Princeton University and a doctorate in biochemical engineering from Massachusetts Institute of Technology. Over the last 17 years at Amgen, Margaret has been responsible for formulation development and commercial formulation support. Her research interests are in the areas of protein aggregation, IgG2 disulfide heterogeneity, surface interactions, and glass delamination.
Aliasger Salem is an associate professor of pharmaceutics and translational therapeutics at the University of Iowa College of Pharmacy and leader of the Cancer Signaling and Experimental Therapeutics Program at the Holden Comprehensive Cancer Center.
Satish Singh, Ph.D., is research fellow at Pfizer, where his responsibilities include leading product development activities for biologics, vaccines, and oligonucleotides. He has more than 20 years of experience in the industry in product development of oral dosage forms, ophthalmics, and parenterals, and he has been involved in the submission of several biologics license applications and investigational new drugs.
Sven Stegemann, Ph.D., is director of Pharmaceutical Business Development at Capsugel, the world’s leading provider of dosage form solutions to the healthcare industry. Stegemann is a pharmacist by training and holds a doctorate in pharmacology. His scientific interest is in improving drug therapy in older adults through multidisciplinary and patient-centered science.
Jan Willem van der Laan
Jan Willem van der Laan is pharm/tox assessor for the Medicines Evaluation Board, chair of the European Medicines Agency Safety Working Party, and has been involved in activities at the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use for 20 years.
Liu Yuanjie, Ph.D. candidate, is the chairperson of the AAPS National University of Singapore student chapter. The chapter was awarded as the 2012 AAPS Student Chapter of the Year.
Hongwei Zhang, Ph.D., is assistant professor in the Department of Pharmaceutical Sciences at South Dakota State University. His research is focused on gene/RNAi delivery. Hongwei received the AAPS Biotechnology Innovation Award in 2010 for his work on rAAV-mediated CNS gene delivery.
Catherine began her tenure at AAPS in 2010 as the journals editorial assistant while she completed her master’s degree in publishing at George Washington University. She then became the Web content manager for the newly redesigned AAPS Web site in 2011. Catherine enjoys traveling, cooking, and spending time outside on sunny days.
Kimberly Brown, M.A., has served as communications and social media manager at AAPS since 2011. She received her Master of Arts in communications from Trinity Washington University. A self-proclaimed foodie, Kim spends her spare time dining at new restaurants and attending live concert performances.
Stacey has served as AAPS director of Public Outreach since 2002. She has a Master of Arts in molecular and cellular biology and biochemistry. When not meeting with graduate students, Stacey enjoys teaching her young kids about science.
Megan McNear is the AAPS senior public outreach specialist.
Todd joined AAPS in 2012 with 20 years of experience in scholarly and scientific publishing and a keen interest in Web publishing and electronic learning. He holds bachelor’s degrees in mathematics and history and, in his spare time, enjoys basketball, gardening, and cooking.
Charles “Chuck” Salvetti
Charles “Chuck” Salvetti is the AAPS member services manager/business systems analyst. Prior to working at AAPS, he served as the director, chapter services for the American Society for Training and Development in Alexandria, Va. He also spent more than ten years as the student and young professional (YP) programs manager at the Society for Human Resource Management (SHRM). At SHRM, Chuck was responsible for overseeing the student and YP membership programs, student chapter operations, and the College Relations Core Leadership Area. In his spare time, he enjoys learning about (and using) new technology, reading about world’s fairs, and riding roller coasters.